Incyte Corporation (NASDAQ:INCY) has exceptional know-how in medicinal chemistry and biology. The global company was founded under a strong motivation, which defined the need for a relentless pursuit of R&D excellence. It believes that this was the only way to translate into new solutions, which would positively impact the lives of patients.
Through Novartis, the company has been conducting a pivotal Phase 2 GEOMETRY mono-1 study on Tabrecta™ (capmatinib). This is supposedly a treatment for adult patients struggling with metastatic non-small cell lung cancer (NSCLC). With this condition, their tumors probably have a mutation likely to result in MET exon 14 (METex14).
Incyte is enthusiastic about the results of Tabrecta, the fourth molecule to be discovered by its scientists. The study results, which have been published in The New England Journal of Medicine.1 had positive overall response rates (ORR).
METex14 as an Important Biomarker for Physicians to Consider
The GEOMETRY mono-1 study engaged 14 patients. Thirteen of them had with METex14 had brain metastases at baseline and were considered evaluable by the BIRC.1. Peripheral edema, vomiting, nausea, and increased blood creatinine were some of the reported treatment-related adverse events notable in grades 1 and 2.
As a receptor tyrosine kinase coded by the MET gene, MET is an important part of cell signaling, proliferation, and survival. Thus it is an important consideration for physicians when choosing metastatic NSCLC treatment options. Besides, the GEOMETRY mono-1 study proved that Tabrecta has the potential of providing patients with metastatic METex14 NSCLC.
“Having a therapy that targets a recognized oncogenic driver offers a much-needed treatment option for patients living with this aggressive form of lung cancer…’’ Incyte’s Chief Medical Officer, Steven Stein. He was expounding on the company’s fulfillment in being able to contribute to an unmet medical need.
Meanwhile, Tabrecta is the only FDA-approved therapy. On the other hand, Novartis will have exclusive worldwide rights to develop and commercialize the therapy. This will give Incyte a total of more than $500 million in milestones in addition to royalties of between 12-14% on the global network of Tabrecta’s sales from Novartis.
